TO THE EDITOR
Increased CD38 expression on the surface of neoplastic lymphocytes in chronic lymphocytic leukemia (CLL) has recently been recognized as an important poor prognostic factor. 1 Angiogenesis appears to play a central role in the pathophysiology of hematopoietic malignancies, including CLL. 2 In early-stage CLL, increased bone marrow microvessel density correlated with reduced progression-free survival and bone marrow expression of the angiogenic factor, vascular endothelial growth factor (VEGF), 3 while the mean fluorescence intensity of expression of VEGF on CLL cells was higher in cases with progressive disease. 4 In contrast, lower levels of intracellular VEGF in peripheral blood CLL cells were associated with shorter survival times in patients with early-stage disease. 5 Elevated blood levels of VEGF, basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) have been reported in CLL. 6 We hypothesized that increased CD38 expression on CLL cells might be associated with increased expression of angiogenic markers, in particular, VEGF. We, therefore, measured the surface expression of CD38 and VEGF (using clone 26503, mouse IgG 2b from R&D Systems as anti-VEGF monoclonal antibody with specificity for both VEGF 165 and 121 isoforms 4 ) on peripheral blood circulating CD19/CD5 cells using triple-color flow cytometry (Coulter EPICS-XL) in 28 consecutive patients (mean age 66 years, range 35-85: 17 male, 11 female) with newly diagnosed, untreated CLL (19 Binet stage A, four Binet stage B, five Binet stage C). Only CLL patients who had 480% CD19 cells co-expressing CD5 were included in the study. In addition, serum levels of VEGF, HGF and bFGF were measured in duplicate by enzyme-linked immunosorbent assay (ELISA). Results of the above tests were also correlated with Binet stage, complete blood count and serum LDH, beta 2 microglobulin and CRP. Surface expression of VEGF on the peripheral blood CD19 B cells of 20 normal controls (mean age 39 years, range 26-57: seven male, 13 female) was measured by dual-color flow cytometry. The study was approved by the local Hospital ethics committee, and subjects in the study gave informed, written consent. Calculation of Pearson's coefficient was used when comparing two continuous variables. Student's t-test and oneway ANOVA test were used to determine the statistical significance of the mean value difference between groups.
Mean (s.d.; range) % expression of CD38 and VEGF on the CLL cells was 36% (28.9; 0-81) and 46% (30.4; 0-93), respectively. The mean % expression of VEGF on the CLL cells was significantly higher than the mean % VEGF expression of 7% on the normal B lymphocytes of the control group (P ¼ 0.0001). There was a strong correlation between the % of CLL cells expressing CD38 and % of cells expressing VEGF (P ¼ 0.001). The % of CLL cells expressing CD38 also correlated significantly with lymphocyte count (Po0.05). For CD38 þ CLL cases (430% of CD19 þ , CD5 þ cells co-expressing CD38 1 ) (n ¼ 14), the mean % of cells expressing VEGF was 68%, compared to 21% for CD38À CLL cases (n ¼ 14) (P ¼ 0.0001). The mean (s.d.; range) serum levels of VEGF, HGF and bFGF were 216 (221; 24-1095), 1487 (811; 760-4889) and 14 pg/ml (21; 0-89), respectively. There was no significant correlation between the % of CLL cells expressing CD38 or VEGF and serum VEGF or serum bFGF. Serum HGF showed a significant correlation with lymphocyte count (Po0.001) and a nonstatistically significant positive correlation with the % of CLL cells expressing CD38 (r ¼ 0.329). Patients with Binet stage C disease had significantly higher % of CLL cells expressing CD38 (Po0.05) and significantly higher serum HGF levels (Po0.05) compared to those with stage A or B.
Our results show a strong correlation between the expression of CD38 and VEGF on tumor cells in the peripheral blood of untreated CLL patients, as well as some degree of positive correlation between CD38 expression and serum HGF, suggesting the possibility that angiogenic factors might contribute to the more aggressive clinical behaviour of CD38 þ CLL. Cellular expression of VEGF and/or other angiogenic peptides appears to play an important role in the pathophysiology of hematopoietic malignancies, not only as promoters of new vessel formation but also in hematopoietic malignant cell growth and survival by paracrine and/or autocrine mechanisms. 7 We could not find any correlation between the expression of either CD38 or VEGF on the CLL cells and serum VEGF and bFGF. Others have reported a lack of correlation between bone marrow angiogenesis and serum VEGF 3 and between serum and intracellular VEGF levels 8 in CLL, perhaps due to contributions to serum VEGF levels from other sources. Also, serum levels of bFGF may not accurately reflect any possible contribution to angiogenesis by bFGF because of low cellular release of bFGF. 8 We are currently investigating the relationship between CD38 expression in CLL and other measures of angiogenesis, in particular bone marrow microvessel density and VEGF expression. The demonstration of more conclusive evidence of increased angiogenesis associated with increased surface expression of VEGF could provide a rationale for the use of antiangiogenic agents in CD38 þ CLL.
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This study was supported by a grant from the Irish Cancer Society. in which they proposed to stratify patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) post interferon alpha failure treated with imatinib mesylate into different risk groups. In a multivariate analysis of 145 patients, they identified low neutrophil counts o10 9 /l 6-12 weeks into therapy and a poor cytogenetic response (Ph-positive cells 465%) at 3 months to be independent poor prognostic factors. Each factor was assigned a score of 1. Patients were then divided into three risk groups: low (score 0; 35%), intermediate (score 1; 36%), and high (score 2; 29%). The estimated 2-year survival rates were 100, 82, and 40%, respectively (Po0.0001). The estimated 2-year progression-free survival rates were 100, 66, and 15%, respectively (Po0.0001). The risk score was validated in an independent patient population (presumably from the British studies).
Since different study groups may have different prognostically relevant patient and leukemic cell characteristics undetected by study eligibility criteria (latent prognostic variables), we investigated the relevance of the new risk score in our study group of 258 patients with Ph-positive chronic phase CML post interferon alpha failure treated with imatinib. In all, 221 patients were evaluable by the two prognostic factors. Their outcome is shown in the Table 1 below.
While a poor cytogenetic response at 3 months was predictive of worse outcome (2-year survival rates 98% vs 85%; Po0.001), survival by neutropenia o10
9 /l at 6-12 weeks gave a paradoxic result (estimated 2-year survival rate of 100% with neutropenia vs 88% without neutropenia; P ¼ 0.006). This was because a subset of patients without neutropenia had a brief period of complete hematologic response before developing resistance and transformation/death from CML. Of note, even the worst risk group in our study (corresponding to the intermediate risk group according to the Marin model) had estimated 2-year progression-free and survival rates of 80% (vs 15 and 40%, respectively, in the study of Marin et al). In a multivariate analysis, we had found prolonged myelosuppression anytime during therapy with imatinib (grade 3-4 neutropenia or thrombocytopenia) to be independently associated with worse response to imatinib. 
